7-Chloro-1,2,3,4-tetrahydrobenzo[b]azepin-5-one CAS 160129-45-3 Tolvaptan Intermediate

Short Description:

Name: 7-Chloro-1,2,3,4-tetrahydrobenzo[b]azepin-5-one 

CAS: 160129-45-3

Purity: ≥99.0% (HPLC)

Appearance: Light Green to Light Yellow Powder

Intermediate of Tolvaptan (CAS 150683-30-0) for the treatment of Hyponatremia

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

 


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 7-Chloro-1,2,3,4-tetrahydrobenzo[b]azepin-5-one
Synonyms 7-Chloro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one; 7-Chloro-3,4-dihydro-1H-benzo[b]azepin-5(2H)-one
CAS Number 160129-45-3
CAT Number RF-PI395
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C10H10ClNO
Molecular Weight 195.65
Melting Point 103.0 to 107.0℃
Solubility Soluble in Methanol
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Light Green to Light Yellow Powder
Identification Methods NMR, HPLC
Purity / Analysis Method ≥99.0% (HPLC)
Loss on Drying ≤1.0%
Residue on Ignition ≤0.50%
Any Single Impurity ≤0.50%
Total Impurities ≤1.0%
Test Standard Enterprise Standard
Usage Intermediate of Tolvaptan (CAS 150683-30-0), treatment of Hyponatremia

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

1

FAQ:

Application:

7-Chloro-1,2,3,4-tetrahydrobenzo[b]azepin-5-one (CAS 160129-45-3) is an intermediate in the synthesis of Tolvaptan (CAS 150683-30-0). Tolvaptan is a selective, competitive orally active nonpeptide arginine vasopressin V2 receptor antagonist with an IC50 of 1.28µM for the inhibition of AVP-induced platelet aggregation. Tolvaptan is used to treat hyponatremia associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone. Tolvaptan is also in fast-track clinical trials for polycystic kidney disease. Treatment with Tolvaptan causes rapid and sustained body weight reductions concurrent with increases in urine output, improves and/or normalizes serum sodium in hyponatremic patients, reduces signs and symptoms of congestion and increases thirst.

  • Write your message here and send it to us